Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...

A new review was published in Volume 18 of Aging on May 30, 2026, titled "The love and hate relationship between cellular ...

The high-grade glioma market is witnessing steady growth driven by the rising incidence of aggressive brain tumors, increasing awareness, and advancements ...

By David Bautz, PhD NASDAQ: BDRX READ THE FULL BDRX RESEARCH REPORT Business Update Expanding Phase 3 Serenta Trial into Canada On June 29, 2026, Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) announced ...

Despite fears of an innovation slowdown, stoked by funding cuts and FDA personnel shakeups, the agency approved 17 ...

Protein is one of the most talked-about nutrients in sport. It is also one of the easiest to oversimplify. On one side, there ...

The FDA has granted Fast Track designation to BM-3103, a novel topical mTOR inhibitor for epidermolysis bullosa simplex currently in phase 2.

Spinal degeneration remains one of the leading causes of chronic disability globally, with surgical management representing a ...

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while ...